Cationic derivative of polyprenol, a potential component of liposomal drug carriers, does not alter renal function in rats
PBN-AR
Instytucja
Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk
Informacje podstawowe
Główny język publikacji
en
Czasopismo
EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY
ISSN
1438-7697
EISSN
1438-9312
Wydawca
WILEY-BLACKWELL
DOI
URL
Rok publikacji
2014
Numer zeszytu
5
Strony od-do
659-662
Numer tomu
116
Identyfikator DOI
Liczba arkuszy
0,43
Słowa kluczowe
en
Nephrotoxicity
Liposomes
Drug delivery
Cationic polyprenoid
Renal haemodynamics
Streszczenia
Język
en
Treść
Potential toxicity of a cationic derivative of polyprenol (APren-7) with lipofecting activity was examined, especially its influence on renal haemodynamics and function, in order to conduct further investigation of its suitability as a component of liposomal drug carriers. Sprague-Dawley rats received daily injections (0.5mL, s.c.) of liposomes comprised of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and APren-7 (LP); classic liposomes composed of DOPE only (L); water solvent (W). After 4 weeks rats were anaesthetised and a wide spectrum of functional parameters were measured. These included mean arterial blood pressure (MBP), total renal blood flow (RBF), renal cortical, outer and inner medullary blood flow (CBF, OMBF, IMBF, respectively), diuresis, and sodium and solute excretion. Most parameters did not significantly differ between treated and control groups. A lower OMBF/IMBF ratio in liposome-treated groups (L: 1.00.1; LP: 1.1 +/- 0.1 vs. W: 1.9 +/- 0.3, p<0.05) might be an early sign of renal function impairment, however, since the lowering occurred in both L and LP groups, there was no reason to suspect that APren-7 had any untoward influence on renal haemodynamics or excretion. The present results did not reveal toxic effects of APren-7 in experimental rats, indicating that it could be suitable as a component of liposomal drug carriers. Practical applications: Many currently used drugs have severe side effects, which present a serious problem in the treatment of numerous diseases. Searching for compounds augmenting efficacy of drugs to reduce their dosage seems to be a promising strategy. This can be accomplished by facilitating the bioavailability of the drug, e.g. by improving penetration of biological membranes or delivery to the areas distant from the lumen of blood vessels and in particular instances by improving drug stability. The cationic derivative of polyprenol APren-7 has lipofecting properties. In this study we found APren-7 to be harmless to the experimental animals. Newly designed liposomal carriers could find application not only in the pharmaceutical and cosmetics industry but also in biological laboratories and in molecular medicine.
Cechy publikacji
short communication
Inne
System-identifier
592422
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych